MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ajcn/nqab390

Медицинская библиотека · The American journal of clinical nutrition · 2022

Clinical and biomarker modifiers of vitamin D treatment response: the Multi-Ethnic Study of Atherosclerosis.

Hsu Simon, Prince David K, Williams Kayleen, Allen Norrina B, Burke Gregory L, Hoofnagle Andrew N, Li Xiaohui, Liu Kiang J, McClelland Robyn L, Michos Erin D, Psaty Bruce M, Shea Steven J, Rice Kenneth M, Rotter Jerome I, Siscovick David, Tracy Russell P, Watson Karol E, Kestenbaum Bryan R, de Boer Ian H

СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

Different 25-hydroxyvitamin D [25(OH)D] thresholds for treatment with vitamin D supplementation have been suggested and are derived almost exclusively from observational studies. Whether other characteristics, including race/ethnicity, BMI, and estimated glomerular filtration rate (eGFR), should also influence the threshold for treatment is unknown.

OBJECTIVES

The aim was to identify clinical and biomarker characteristics that modify the response to vitamin D supplementation.

METHODS

A total of 666 older adults in the Multi-Ethnic Study of Atherosclerosis (MESA) were randomly assigned to 16 wk of oral vitamin D3 (2000 IU/d; n = 499) or placebo (n = 167). Primary outcomes were changes in serum parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations from baseline to 16 wk.

RESULTS

Among 666 participants randomly assigned (mean age: 72 y; 53% female; 66% racial/ethnic minority), 611 (92%) completed the study. The mean (SD) change in PTH was -3 (16) pg/mL with vitamin D3 compared with 2 (18) pg/mL with placebo (estimated mean difference: -5; 95% CI: -8, -2 pg/mL). Within the vitamin D3 group, lower baseline 25-hydroxyvitamin D [25(OH)D] was associated with a larger decline in PTH in a nonlinear fashion. With baseline 25(OH)D ≥30 ng/mL as the reference, 25(OH)D <20 ng/mL was associated with a larger decline in PTH with vitamin D3 supplementation (-10; 95% CI: -15, -6 pg/mL), whereas 25(OH)D of 20-30 ng/mL was not (-2; 95% CI: -6, 1 pg/mL). A segmented threshold model identified a baseline 25(OH)D concentration of 21 (95% CI: 13, 31) ng/mL as an inflection point for difference in change in PTH. Race/ethnicity, BMI, and eGFR did not modify vitamin D treatment response. There was no significant change in 1,25(OH)2D in either treatment group.

CONCLUSIONS

Of characteristics most commonly associated with vitamin D metabolism, only baseline 25(OH)D <20 ng/mL modified the PTH response to vitamin D supplementation, providing support from a clinical trial to use this threshold to define insufficiency. This trial was registered at clinicaltrials.gov as NCT02925195.

Для цитирования: Hsu Simon, Prince David K, Williams Kayleen, Allen Norrina B, Burke Gregory L, Hoofnagle Andrew N, Li Xiaohui, Liu Kiang J, McClelland Robyn L, Michos Erin D, Psaty Bruce M, Shea Steven J, Rice Kenneth M, Rotter Jerome I, Siscovick David, Tracy Russell P, Watson Karol E, Kestenbaum Bryan R, de Boer Ian H. Clinical and biomarker modifiers of vitamin D treatment response: the Multi-Ethnic Study of Atherosclerosis.. The American journal of clinical nutrition. 2022. DOI: 10.1093/ajcn/nqab390.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.